278 related articles for article (PubMed ID: 26944602)
1. Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.
Jeon J; Kim W; Jang J; Isacson O; Seo H
Neuroscience; 2016 Jun; 324():20-8. PubMed ID: 26944602
[TBL] [Abstract][Full Text] [Related]
2. Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington's disease model mice.
Kim W; Seo H
Biochem Biophys Res Commun; 2014 Jan; 443(2):706-11. PubMed ID: 24333873
[TBL] [Abstract][Full Text] [Related]
3. Proteasome activator enhances survival of Huntington's disease neuronal model cells.
Seo H; Sonntag KC; Kim W; Cattaneo E; Isacson O
PLoS One; 2007 Feb; 2(2):e238. PubMed ID: 17327906
[TBL] [Abstract][Full Text] [Related]
4. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.
Alto LT; Chen X; Ruhn KA; Treviño I; Tansey MG
PLoS One; 2014; 9(5):e96544. PubMed ID: 24824433
[TBL] [Abstract][Full Text] [Related]
5. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
Xie Y; Hayden MR; Xu B
J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
[TBL] [Abstract][Full Text] [Related]
6. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
Seo H; Kim W; Isacson O
Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
[TBL] [Abstract][Full Text] [Related]
7. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
[TBL] [Abstract][Full Text] [Related]
8. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
[TBL] [Abstract][Full Text] [Related]
9. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
[TBL] [Abstract][Full Text] [Related]
10. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
Bett JS; Goellner GM; Woodman B; Pratt G; Rechsteiner M; Bates GP
Hum Mol Genet; 2006 Jan; 15(1):33-44. PubMed ID: 16311253
[TBL] [Abstract][Full Text] [Related]
11. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease.
Kacher R; Lamazière A; Heck N; Kappes V; Mounier C; Despres G; Dembitskaya Y; Perrin E; Christaller W; Sasidharan Nair S; Messent V; Cartier N; Vanhoutte P; Venance L; Saudou F; Néri C; Caboche J; Betuing S
Brain; 2019 Aug; 142(8):2432-2450. PubMed ID: 31286142
[TBL] [Abstract][Full Text] [Related]
12. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.
Brown TB; Bogush AI; Ehrlich ME
Hum Mol Genet; 2008 Oct; 17(20):3095-104. PubMed ID: 18632688
[TBL] [Abstract][Full Text] [Related]
13. C57BL/6 Background Attenuates mHTT Toxicity in the Striatum of YAC128 Mice.
Back MK; Kurzawa J; Ruggieri S; von Engelhardt J
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884469
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
[TBL] [Abstract][Full Text] [Related]
15. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
16. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
[TBL] [Abstract][Full Text] [Related]
17. AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington's disease.
Connor B; Sun Y; von Hieber D; Tang SK; Jones KS; Maucksch C
Gene Ther; 2016 Mar; 23(3):283-95. PubMed ID: 26704721
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease.
Hunter JM; Lesort M; Johnson GV
J Neurosci Res; 2007 Jun; 85(8):1774-88. PubMed ID: 17455294
[TBL] [Abstract][Full Text] [Related]
19. Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease.
Anglada-Huguet M; Giralt A; Rué L; Alberch J; Xifró X
Biochim Biophys Acta; 2016 Jul; 1862(7):1255-66. PubMed ID: 27063456
[TBL] [Abstract][Full Text] [Related]
20. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies.
Schipper-Krom S; Juenemann K; Jansen AH; Wiemhoefer A; van den Nieuwendijk R; Smith DL; Hink MA; Bates GP; Overkleeft H; Ovaa H; Reits E
FEBS Lett; 2014 Jan; 588(1):151-9. PubMed ID: 24291262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
